Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817931 · ClinicalTrials.gov registry record · Phase 4
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
A Phase 4 study of Dementia and Overactive Bladder, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT03817931: Completed Phase 4 study of Dementia and Overactive Bladder, sponsored by Baylor Research Institute.
NCT03817931 is a Phase 4 study of Dementia and Overactive Bladder that has completed, run by Baylor Research Institute. The registered enrollment target is 12 participants, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03817931, a Phase 4 study of Dementia and Overactive Bladder, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded intervention for 30 days.
Primary Outcome
Functional connectivity during a word recognition task will be compared within subjects from baseline and after 29+/- 1 day of intervention medication.
Conditions Studied
Interventions
- DRUG Anticholinergic
- DRUG Beta-3 Agonists, Adrenergic
- DIAGNOSTIC_TEST Functional magnetic resonance imaging (fMRI)
- DIAGNOSTIC_TEST Rey Auditory Verbal Learning Test (RAVLT)
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Baylor Scott and White Health - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2022-02-26 |
| Phase | Phase 4 |
What the finished NCT03817931 record still lists
NCT03817931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 7,723-participant average among 199 other Dementia trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Dementia appearing as the primary indexed condition, and to 4 interventions - of which Anticholinergic is the first listed.
NCT03817931 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03817931 about?
NCT03817931 is a clinical study titled "Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder". Women presenting with overactive bladder symptoms will be randomized to one of 3 arms (anticholinergic, beta-3 agonist, placebo). They will undergo baseline cognitive testing, functional MRI of the brain. Cognitive testing and functional MRI will be repeated after taking their double blinded interve...
What is the current status of trial NCT03817931?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2019-08-05. Estimated completion is 2022-02-26.
What conditions does trial NCT03817931 study?
This clinical trial studies the following conditions: Dementia, Overactive Bladder, Lower Urinary Tract Symptoms, Incontinence, Urge.
What interventions are being tested in trial NCT03817931?
The interventions under investigation include: Anticholinergic (DRUG), Beta-3 Agonists, Adrenergic (DRUG), Functional magnetic resonance imaging (fMRI) (DIAGNOSTIC_TEST), Rey Auditory Verbal Learning Test (RAVLT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03817931?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817931 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03817931's enrollment target sits among peer trials
12 195th of 199 higher than 5 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
COMPLETED · Phase 4
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI